Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI5752 in Japanese patients with advanced solid tumors
NCT05685472Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2022
- Primary completion
- Aug 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of volrustomig in solid tumor, sponsored by AstraZeneca. Primary endpoints: The number of subjects experiencing treatment related adverse events (AEs), The number of subjects experiencing treatment related serious adverse events (SAEs) and 4 more. Started Dec 2022; status: completed.
02
Drugs
volrustomig
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05685472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05685472.